## Max Yates

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9085537/publications.pdf

Version: 2024-02-01

30 papers	1,432 citations	932766 10 h-index	22 g-index
30	30	30	2020
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.5	940
2	ANCA-associated vasculitis. Clinical Medicine, 2017, 17, 60-64.	0.8	153
3	Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clinical Rheumatology, 2014, 33, 227-236.	1.0	51
4	Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial. Journal of Rheumatology, 2015, 42, 1177-1185.	1.0	44
5	Oncological Emergency Admissions to the Norfolk and Norwich University Hospital: An Audit of Current Arrangements and Patient Satisfaction. Clinical Oncology, 2009, 21, 226-233.	0.6	43
6	The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskeletal Disorders, 2016, 17, 285.	0.8	41
7	Body Mass Index, Smoking, and Alcohol and Risks of Barrett's Esophagus and Esophageal Adenocarcinoma: A UK Prospective Cohort Study. Digestive Diseases and Sciences, 2014, 59, 1552-1559.	1.1	38
8	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	1.8	23
9	Impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases in the UK: a mixed-methods study. BMJ Open, 2021, 11, e048772.	0.8	18
10	The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology, 2017, 56, kew397.	0.9	16
11	Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study. Rheumatology, 2020, 59, 319-323.	0.9	11
12	Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. Clinical and Experimental Rheumatology, 2017, 35, 1-2.	0.4	11
13	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. Journal of Rheumatology, 2020, 47, 1379-1384.	1.0	10
14	Conventional and biological immunosuppressants in vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 94-111.	1.4	9
15	Pyomyositis. Journal of Diabetes and Its Complications, 2011, 25, 346-348.	1.2	8
16	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. Journal of Rheumatology, 2019, 46, 1360-1364.	1.0	5
17	Clinical and biomechanical factors associated with falls and rheumatoid arthritis: baseline cohort with longitudinal nested case–control study. Rheumatology, 2022, 61, 679-687.	0.9	3
18	Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis?: Table 1. Rheumatology, 2016, 55, 769-772.	0.9	2

#	Article	IF	CITATIONS
19	Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study. Annals of the Rheumatic Diseases, 2019, 78, 704-705.	0.5	2
20	Accessing health services for musculoskeletal diseases during early COVID-19 lockdown: Results from a UK population survey. Rheumatology Advances in Practice, 2020, 4, rkaa047.	0.3	2
21	Does the co-existence of acute anterior uveitis and chronic back pain prompt primary care physicians to consider a diagnosis of axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2016, 75, e18-e18.	0.5	1
22	Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?. Current Rheumatology Reports, 2022, 24, 111-117.	2.1	1
23	Acute and general medicine for the physician. Clinical Medicine, 2010, 10, 577-578.	0.8	0
24	ANCA-associated vasculitis – Should we change the standard of care?. Indian Journal of Rheumatology, 2015, 10, S54-S58.	0.2	0
25	088â€fCardiovascular risk factors are associated with the onset of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective cohort: EPIC-Norfolk study. Rheumatology, 2018, 57, .	0.9	0
26	O14â€fPro-inflammatory diets are associated with increased C-reactive protein and subsequent rheumatoid arthritis in the European Investigation of Cancer: Norfolk Arthritis Register cohort. Rheumatology, 2019, 58, .	0.9	0
27	215â€fPredictors of resilience in severe rheumatoid arthritis: an analysis of data from the Norfolk Arthritis Register. Rheumatology, 2019, 58, .	0.9	0
28	217â€fResults of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica. Rheumatology, 2019, 58, .	0.9	0
29	FRIO657â€METABOLIC SYNDROME PRECEDES THE ONSET OF HIP AND KNEE PAIN AND THE RISK IS NOT MODIFIED BY DIET OR CHANGES IN BMI. , 2019, , .		0
30	Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study. Annals of the Rheumatic Diseases, 2020, 79, 547-549.	0.5	0